Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Clin Cancer Res
    October 2025
  1. LIU R, Wang X, Branigan TB, Griffin D, et al
    BET bromodomain inhibition reverses CDK4/6 inhibitor resistance in estrogen receptor-positive breast cancer via induction of miR-34a-5p.
    Clin Cancer Res. 2025 Oct 7. doi: 10.1158/1078-0432.CCR-25-1406.
    >> Share

  2. MURDTER TE, Schroth W, Goetz MP, Tremmel R, et al
    Supplementation of Tamoxifen with low-dose Endoxifen in breast cancer patients with impaired tamoxifen metabolism (TAMENDOX): a randomized controlled phase 1/2 trial.
    Clin Cancer Res. 2025 Oct 2. doi: 10.1158/1078-0432.CCR-25-2103.
    >> Share

    September 2025
  3. GUIU S, Balmana J, Lemercier P, Follana P, et al
    Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER+/HER2- breast cancer and selected genomic alterations: results of the DOLAF trial.
    Clin Cancer Res. 2025 Sep 23. doi: 10.1158/1078-0432.CCR-24-4221.
    >> Share

  4. REED SC, Potts CR, Luo L, Davidson BA, et al
    Clonal hematopoiesis of indeterminate potential influences breast cancer outcomes in a genotype-specific manner.
    Clin Cancer Res. 2025 Sep 19. doi: 10.1158/1078-0432.CCR-25-2009.
    >> Share

  5. KOLBERG HC, Schumacher J, Erber R, Braun M, et al
    Atezolizumab monotherapy window preceding combined neoadjuvant chemo- and immune therapy in triple negative breast cancer (TNBC) - the neoMono trial.
    Clin Cancer Res. 2025 Sep 11. doi: 10.1158/1078-0432.CCR-25-1288.
    >> Share

  6. MIGLIETTA F, De Graaf M, Vernieri C, Piacentini F, et al
    Prognosis and biological characteristics of ER-low metastatic breast cancer: results from a multicenter cohort and the TONIC trial.
    Clin Cancer Res. 2025 Sep 4. doi: 10.1158/1078-0432.CCR-25-1796.
    >> Share

  7. PETRICOIN EF, Wolf DM, Yau C, Wulfkuhle JD, et al
    Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer.
    Clin Cancer Res. 2025 Sep 4:OF1-OF11. doi: 10.1158/1078-0432.CCR-25-0553.
    >> Share

    August 2025
  8. ROYCE M, Shah M, Zhang L, Cheng J, et al
    FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer.
    Clin Cancer Res. 2025 Aug 27:10.1158/1078-0432.CCR-25-1388.
    >> Share

  9. PATEL RJS, Wu C, Stowers CE, Mohamed RM, et al
    MRI-based mathematical modeling to predict the response of I-SPY 2 breast cancer patients to neoadjuvant therapy.
    Clin Cancer Res. 2025 Aug 26. doi: 10.1158/1078-0432.CCR-25-0668.
    >> Share

  10. GERRATANA L, Reduzzi C, Ren Y, Jeselsohn R, et al
    Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study.
    Clin Cancer Res. 2025 Aug 25. doi: 10.1158/1078-0432.CCR-25-0327.
    >> Share

  11. JEON SH, Suh KJ, Jung S, Jeon M, et al
    Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancer.
    Clin Cancer Res. 2025 Aug 20. doi: 10.1158/1078-0432.CCR-24-3283.
    >> Share

  12. BAIRD RD, Bermejo de Las Heras B, Ruiz-Borrego M, Vaklavas C, et al
    Camizestrant in combination with three globally approved CDK4/6 inhibitors in women with ER+, HER2- advanced breast cancer: Results from SERENA-1.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-1198.
    >> Share

  13. KJELDSTED E, Ammitzboll G, Laenkholm AV, Rasic D, et al
    Effects of supervised exercise during neoadjuvant chemotherapy on tumour response in patients with breast cancer (Neo-train): a randomised controlled trial.
    Clin Cancer Res. 2025 Aug 11. doi: 10.1158/1078-0432.CCR-25-0416.
    >> Share

    July 2025
  14. WESOLOWSKI R, Rugo HS, Specht JM, Han H, et al
    Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer.
    Clin Cancer Res. 2025 Jul 25. doi: 10.1158/1078-0432.CCR-25-0992.
    >> Share

  15. LICATA L, Mariani M, Viale G, Dent R, et al
    Timing of Recurrence After Neoadjuvant Chemo-Immunotherapy in Early-Stage Triple-Negative Breast Cancer.
    Clin Cancer Res. 2025 Jul 21. doi: 10.1158/1078-0432.CCR-25-1478.
    >> Share

  16. GONZALEZ-ERICSSON PI, Unni N, Jhaveri K, Stringer-Reasor E, et al
    Phase Ib Trial of Fulvestrant, Palbociclib and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Jul 8. doi: 10.1158/1078-0432.CCR-24-3803.
    >> Share

  17. KIMBUNG S, Veerla S, Muhammad K, Ehinger A, et al
    Global Transcriptional Complexity of Estrogen Receptor-Low Positive Breast Cancers in the Prospective Swedish Population-Based SCAN-B Cohort.
    Clin Cancer Res. 2025;31:2695-2709.
    >> Share

    June 2025
  18. ROJO F, Taylor CR, Barrios C, Torrecillas L, et al
    FOXC1 expression predicts capecitabine efficacy in triple-negative breast cancer patients from the GEICAM_CIBOMA trial.
    Clin Cancer Res. 2025 Jun 26. doi: 10.1158/1078-0432.CCR-25-0338.
    >> Share

  19. MCTIERNAN A
    In Motion: Experimental Evidence on Exercise and Breast Cancer in Women and Mice.
    Clin Cancer Res. 2025 Jun 18. doi: 10.1158/1078-0432.CCR-25-1313.
    >> Share

  20. DE GROOT AF, Cohen D, Heijns JB, Mandigers CMPW, et al
    Ribociclib-letrozole combination as an alternative for neoadjuvant chemotherapy in selected post-menopausal patients with luminal breast cancer (BOOG 2017-01).
    Clin Cancer Res. 2025 Jun 10. doi: 10.1158/1078-0432.CCR-24-3402.
    >> Share

    May 2025
  21. PRIEDIGKEIT N, Harrison B, Shue R, Hughes ME, et al
    Clinicogenomic characterization of inflammatory breast cancer.
    Clin Cancer Res. 2025 May 16. doi: 10.1158/1078-0432.CCR-24-2081.
    >> Share

  22. LI Y, Zhang T, Korkaya H, Liu S, et al
    Correction: Sulforaphane, a Dietary Component of Broccoli/Broccoli Sprouts, Inhibits Breast Cancer Stem Cells.
    Clin Cancer Res. 2025;31:2062.
    >> Share

  23. GWIN WR 3RD, Hurvitz SA
    TOP1 Priority: Advancing Biomarker-Driven Patient Selection for the Use of ADCs.
    Clin Cancer Res. 2025;31:1824-1826.
    >> Share

  24. CHUMSRI S, Larson JJ, Liu E, Tenner KS, et al
    Pembrolizumab in Combination with Binimetinib in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer.
    Clin Cancer Res. 2025;31:1885-1893.
    >> Share

  25. FASCHING PA, Schmatloch S, Hauke J, Rey J, et al
    Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.
    Clin Cancer Res. 2025;31:1596-1604.
    >> Share

    April 2025
  26. CLARK AS, Zhao F, Klein P, Montero AJ, et al
    A Phase II Randomized Study of Paclitaxel alone or combined with Pelareorep with or without Avelumab in Metastatic Hormone Receptor Positive Breast Cancer: the BRACELET-01/PrE0113 study.
    Clin Cancer Res. 2025 Apr 29. doi: 10.1158/1078-0432.CCR-24-2701.
    >> Share

  27. JOHANSSON H, Macis D, Oliva M, Puntoni M, et al
    Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial.
    Clin Cancer Res. 2025 Apr 28:OF1-OF6. doi: 10.1158/1078-0432.CCR-24-2987.
    >> Share

  28. JIAO D, Qiao J, Sun X, Wang C, et al
    Application of Neoadjuvant Docetaxel Plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial.
    Clin Cancer Res. 2025 Apr 21. doi: 10.1158/1078-0432.CCR-25-0289.
    >> Share

  29. YAP TA, Goldman JW, Vinayak S, Tomova A, et al
    First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.
    Clin Cancer Res. 2025 Apr 17. doi: 10.1158/1078-0432.CCR-24-2740.
    >> Share

  30. GOUGH M, Kwah KKX, Khan T, Ghosh S, et al
    Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast Cancers.
    Clin Cancer Res. 2025;31:1504-1519.
    >> Share

  31. JONES LW, Lavery JA, Tsai BL, Moskowitz CS, et al
    A Co-Clinical Trial of Exercise Therapy in Breast Cancer Prevention.
    Clin Cancer Res. 2025 Apr 4. doi: 10.1158/1078-0432.CCR-24-4298.
    >> Share

  32. LIU J, Song C, Yang Y, Wang X, et al
    Safety and Efficacy of KN046 in combination with KN026 in Patients with advanced HER2-positive Breast Cancer: a Phase II Trial.
    Clin Cancer Res. 2025 Apr 4. doi: 10.1158/1078-0432.CCR-24-3888.
    >> Share

    March 2025
  33. JILDERDA MF, Zhang Y, Rebattu V, Salunga R, et al
    Identification of Early-Stage Breast Cancer with Minimal Risk of Recurrence by Breast Cancer Index.
    Clin Cancer Res. 2025 Mar 27. doi: 10.1158/1078-0432.CCR-24-3836.
    >> Share

  34. ADEMUYIWA FO, Ma CX, Weilbaecher K, Suresh R, et al
    Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple negative breast cancer.
    Clin Cancer Res. 2025 Mar 21. doi: 10.1158/1078-0432.CCR-24-3145.
    >> Share

  35. JANNI W, Friedl TWP, Yab TC, Bidard FC, et al
    Clinical validity of repeated circulating tumor cell enumeration as an early treatment monitoring tool for metastatic breast cancer in the PREDICT global pooled analysis.
    Clin Cancer Res. 2025 Mar 18. doi: 10.1158/1078-0432.CCR-24-3108.
    >> Share

    February 2025
  36. FASCHING PA, Slamon D, Nowecki Z, Kukielka-Budny B, et al
    Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial.
    Clin Cancer Res. 2025 Feb 28. doi: 10.1158/1078-0432.CCR-24-1724.
    >> Share

  37. LIN CA, Chica-Parrado MR, Unni N, Jaeger E, et al
    ESR1 Y537S and D538G mutations drive resistance to CDK4/6 inhibitors in estrogen receptor-positive breast cancer.
    Clin Cancer Res. 2025 Feb 25. doi: 10.1158/1078-0432.CCR-24-2307.
    >> Share

  38. POUGOUE KETCHEMEN J, Njotu FN, Babeker H, Monzer A, et al
    Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody-Drug Radioconjugate.
    Clin Cancer Res. 2025;31:685-696.
    >> Share

  39. GOEL S, Jovanovic B, Chu X, Hughes M, et al
    A phase II study of abemaciclib for patients with retinoblastoma-positive, triple-negative metastatic breast cancer.
    Clin Cancer Res. 2025 Feb 5. doi: 10.1158/1078-0432.CCR-24-2647.
    >> Share

  40. DRAKE RJG, Landen AH, Holmberg E, Stenmark Tullberg A, et al
    Endothelial cell pY397-FAK expression predicts risk of breast cancer recurrences after radiotherapy in SweBCG91-RT cohort.
    Clin Cancer Res. 2025 Feb 5. doi: 10.1158/1078-0432.CCR-24-2939.
    >> Share

  41. KOBOLD S
    RORing CAR T Cells in Solid and Hematologic Cancers: Same but Different.
    Clin Cancer Res. 2025;31:437-438.
    >> Share

  42. JAEGER-RUCKSTUHL CA, Specht JM, Voutsinas JM, MacMillan HR, et al
    Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial Malignancies.
    Clin Cancer Res. 2025;31:503-514.
    >> Share

    January 2025
  43. SOOD R, Niemierko A, Ryan L, Spring L, et al
    Impact of Race/Ethnicity on Clinical and Genomic Characteristics, Trial Participation, and Genotype-Matched Therapy among Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Jan 27. doi: 10.1158/1078-0432.CCR-24-2825.
    >> Share

  44. GOUDA MA, Gonugunta A, Dumbrava EE, Yap TA, et al
    Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Jan 22. doi: 10.1158/1078-0432.CCR-24-3468.
    >> Share

  45. RIOS-HOYO A, Xiong K, Dai J, Yau C, et al
    Hormone Receptor-Positive HER2-Negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple-Negative Breast Cancers.
    Clin Cancer Res. 2025;31:403-413.
    >> Share

  46. VIDAL M, Falato C, Pascual T, Sanchez-Bayona R, et al
    Elacestrant in women with estrogen receptor-positive and HER2-negative early breast cancer: results from the preoperative window-of-opportunity ELIPSE trial.
    Clin Cancer Res. 2025 Jan 16. doi: 10.1158/1078-0432.CCR-24-2460.
    >> Share

  47. ELLIOTT MJ, Howarth K, Main S, Fuentes Antras J, et al
    Ultrasensitive Detection and Monitoring of Circulating Tumor DNA using Structural Variants in Early-Stage Breast Cancer.
    Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-3472.
    >> Share

  48. MAURYA SK, Jaramillo-Gomez JA, Rehman AU, Gautam SK, et al
    Mucin5AC promotes breast cancer brain metastasis through cMET/CD44v6.
    Clin Cancer Res. 2025 Jan 6. doi: 10.1158/1078-0432.CCR-24-1977.
    >> Share

  49. HUANG H, Couch RE, Karam R, Hu C, et al
    Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast.
    Clin Cancer Res. 2025;31:130-138.
    >> Share

  50. ABELMAN RO, Wu B, Barnes H, Medford A, et al
    TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2025 Jan 2. doi: 10.1158/1078-0432.CCR-24-2771.
    >> Share

    December 2024
  51. VILLACAMPA G, Llop-Guevara A, Filmann N, Herencia A, et al
    RAD51 testing in patients with early HER2-negative breast cancer and homologous recombination deficiency: post-hoc analysis of the GeparOla trial.
    Clin Cancer Res. 2024 Dec 30. doi: 10.1158/1078-0432.CCR-24-3148.
    >> Share

  52. HAMILTON E, Galsky MD, Ochsenreither S, Del Conte G, et al
    Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
    Clin Cancer Res. 2024;30:5548-5558.
    >> Share

    November 2024
  53. MERIC-BERNSTAM F, Yuca E, Evans KW, Zhao M, et al
    Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models.
    Clin Cancer Res. 2024 Nov 25. doi: 10.1158/1078-0432.CCR-24-1948.
    >> Share

  54. FERRARIO C, Mackey J, Gelmon KA, Levasseur N, et al
    Phase Ib pharmacodynamic study of the MNK inhibitor Tomivosertib (eFT508) combined with paclitaxel in patients with refractory metastatic breast cancer.
    Clin Cancer Res. 2024 Nov 22. doi: 10.1158/1078-0432.CCR-24-0841.
    >> Share

  55. ANAMPA JD, Flynn DL, Leary C, Oh S, et al
    Phase Ib clinical and pharmacodynamic study of the TIE2 kinase inhibitor rebastinib with paclitaxel or eribulin in HER2-negative metastatic breast cancer.
    Clin Cancer Res. 2024 Nov 12. doi: 10.1158/1078-0432.CCR-24-2464.
    >> Share

    October 2024
  56. REDITI M, Fimereli D, Mileva M, Wimana Z, et al
    Integrating molecular imaging and transcriptomic profiling in advanced HER2-positive breast cancer receiving trastuzumab emtansine (T-DM1): an analysis of the ZEPHIR clinical trial.
    Clin Cancer Res. 2024 Oct 29. doi: 10.1158/1078-0432.CCR-24-1007.
    >> Share

  57. NEVEN P, Stahl N, Vidal M, Martin M, et al
    A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from EMBER-2 Study.
    Clin Cancer Res. 2024 Oct 8. doi: 10.1158/1078-0432.CCR-24-2113.
    >> Share

  58. BARDIA A, Cortes J, Bidard FC, Neven P, et al
    Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
    Clin Cancer Res. 2024;30:4299-4309.
    >> Share

    September 2024
  59. DUGO M, Huang CS, Egle D, Bermejo B, et al
    The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2024 Sep 23:OF1-OF10. doi: 10.1158/1078-0432.CCR-24-0149.
    >> Share

  60. QUINTELA-FANDINO M, Bermejo B, Zamora E, Moreno F, et al
    High mechanical conditioning by tumor extracellular matrix stiffness is a predictive biomarker for anti-fibrotic therapy in HER2-negative breast cancer.
    Clin Cancer Res. 2024 Sep 16. doi: 10.1158/1078-0432.CCR-24-1518.
    >> Share

  61. GIORDANO A, Kumthekar PU, Jin Q, Binboga Kurt B, et al
    A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer.
    Clin Cancer Res. 2024 Sep 3. doi: 10.1158/1078-0432.CCR-24-1161.
    >> Share

    August 2024
  62. ROJO F, Najera L, Lirola J, Jimenez J, et al
    Editor's Note: 4E-Binding Protein 1, a Cell Signaling Hallmark in Breast Cancer That Correlates with Pathologic Grade and Prognosis.
    Clin Cancer Res. 2024;30:3641.
    >> Share

  63. GILLMORE R, Xue SA, Holler A, Kaeda J, et al
    Editor's Note: Detection of Wilms' Tumor Antigen-Specific CTL in Tumor-Draining Lymph Nodes of Patients with Early Breast Cancer.
    Clin Cancer Res. 2024;30:3642.
    >> Share

  64. JOVANOVIC B, Church SE, Gorman KM, North K, et al
    Integrative multi-omic profiling of triple-negative breast cancer for identifying suitable therapies.
    Clin Cancer Res. 2024 Aug 13. doi: 10.1158/1078-0432.CCR-23-1242.
    >> Share

  65. PIFFOUX M, Jacquemin J, Petera M, Durand S, et al
    Metabolomic prediction of breast cancer treatment induced neurological and metabolic toxicities.
    Clin Cancer Res. 2024 Aug 6. doi: 10.1158/1078-0432.CCR-24-0195.
    >> Share

    July 2024
  66. DENT RA, Kim SB, Oliveira M, Barrios C, et al
    Ipatasertib plus Paclitaxel for patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial.
    Clin Cancer Res. 2024 Jul 26. doi: 10.1158/1078-0432.CCR-24-0465.
    >> Share

  67. SUN X, Kennedy LC, Gonzalez-Ericsson PI, Sanchez V, et al
    Associations of immune checkpoint predictive biomarkers MHC-I and MHC-II with clinical and molecular features in a diverse breast cancer cohort.
    Clin Cancer Res. 2024 Jul 15. doi: 10.1158/1078-0432.CCR-24-1286.
    >> Share

  68. LLOMBART-CUSSAC A, Perez-Garcia J, Braso-Maristany F, Pare L, et al
    HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial.
    Clin Cancer Res. 2024 Jul 12. doi: 10.1158/1078-0432.CCR-24-0464.
    >> Share

  69. STEARNS V, Jegede OA, Chang VT, Skaar TC, et al
    A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.
    Clin Cancer Res. 2024;30:2709-2718.
    >> Share

    June 2024
  70. SCHMIESTER L, Braso-Maristany F, Gonzalez-Farre B, Pascual T, et al
    Computational model predicts patient outcomes in Luminal B breast cancer treated with endocrine therapy and CDK4/6 inhibition.
    Clin Cancer Res. 2024 Jun 26. doi: 10.1158/1078-0432.CCR-24-0244.
    >> Share

  71. JANK P, Karn T, van Mackelenbergh M, Lindner J, et al
    An analysis of PIK3CA hotspot mutations and response to neoadjuvant therapy in breast cancer patients from four prospective clinical trials.
    Clin Cancer Res. 2024 Jun 5. doi: 10.1158/1078-0432.CCR-24-0459.
    >> Share

  72. ZHANG Q, Cai Z, Gerratana L, Davis AA, et al
    Early evaluation of risk stratification and clinical outcomes for patients with advanced breast cancer through combined monitoring of baseline circulating tumor cells and DNA.
    Clin Cancer Res. 2024 Jun 3. doi: 10.1158/1078-0432.CCR-24-0535.
    >> Share

  73. MAKHLIN I, Demissei BG, D'Agostino R, Hundley WG, et al
    Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial.
    Clin Cancer Res. 2024;30:2370-2376.
    >> Share

    May 2024
  74. GOUGH SM, Flanagan JJ, Teh J, Andreoli M, et al
    Oral estrogen receptor PROTAC(R) vepdegestrant (ARV-471) is highly efficacious as monotherapy and in combination with CDK4/6 or PI3K/mTOR pathway inhibitors in preclinical ER+ breast cancer models.
    Clin Cancer Res. 2024 May 31. doi: 10.1158/1078-0432.CCR-23-3465.
    >> Share

  75. CHEUNG A, Chenoweth AM, Johansson A, Laddach R, et al
    Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth.
    Clin Cancer Res. 2024 May 21. doi: 10.1158/1078-0432.CCR-23-3110.
    >> Share

  76. HADDAD TC, Suman VJ, Giridhar KV, Sideras K, et al
    Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early-stage breast cancer: A prospective trial.
    Clin Cancer Res. 2024 May 16. doi: 10.1158/1078-0432.CCR-24-0341.
    >> Share

  77. WANDER SA, Bardia A
    Cracking the Genomic Code of CDK4/6 Inhibitor Resistance.
    Clin Cancer Res. 2024;30:2008-2010.
    >> Share

  78. BARDIA A, Sun S, Thimmiah N, Coates JT, et al
    Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients.
    Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-24-0428.
    >> Share

    April 2024
  79. BOTTOSSO M, Miglietta F, Vernaci GM, Giarratano T, et al
    Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer.
    Clin Cancer Res. 2024 Apr 24. doi: 10.1158/1078-0432.CCR-23-4020.
    >> Share

  80. IWASE T, Cohen EN, Gao H, Alexander A, et al
    Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy.
    Clin Cancer Res. 2024 Apr 17. doi: 10.1158/1078-0432.CCR-23-2947.
    >> Share

  81. MOYER CL, Lanier A, Qian J, Coleman D, et al
    IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy.
    Clin Cancer Res. 2024 Apr 5. doi: 10.1158/1078-0432.CCR-23-3839.
    >> Share

  82. HAN YJ, Liu S, Hardeman A, Rajagopal PS, et al
    The VEGF-Hypoxia Signature is Upregulated in Basal like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer.
    Clin Cancer Res. 2024 Apr 2. doi: 10.1158/1078-0432.CCR-23-1526.
    >> Share

  83. CONNOLLY RM, Wang V, Hyman DM, Grivas P, et al
    Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
    Clin Cancer Res. 2024;30:1273-1280.
    >> Share

    March 2024
  84. MAGBANUA MJM, Ahmed Z, Sayaman RW, Brown Swigart L, et al
    Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy.
    Clin Cancer Res. 2024 Mar 12. doi: 10.1158/1078-0432.CCR-23-2928.
    >> Share

  85. MARTIN M, Yoder R, Salgado R, Del Monte-Millan M, et al
    Tumor-infiltrating lymphocytes refine outcomes in triple-negative breast cancer treated with anthracycline-free neoadjuvant chemotherapy.
    Clin Cancer Res. 2024 Mar 11. doi: 10.1158/1078-0432.CCR-24-0106.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016